{"title":"Emerging Drugs and Targets for Multiple Sclerosis","subtitle":"","e_issn":null,"url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&scope=site&db=nlebk&AN=2204510&authtype=shib&custid=ns346513","series":"Drug Discovery Series","edition":"","author":"Ana Martinez","contract_publisher":"Lightning Source Inc. (Tier 3)","imprint_publisher":"Royal Society of Chemistry","pub_year":"2019","interest_area":["Neurology"," Internal\/Family Medicine"],"lcc":"RC377 .E44 2019","lcsh":"Multiple sclerosis--Chemotherapy.","language":"eng","format":"EPUB,PDF","downloadable":"","fiction":"False","abridged":"","book_id":"2204510","isbn":"9781788014502","eisbn":"9781788016070","ocn":"1105925628","ddc":"616.8\/34061","isPdfLink":false,"isSAML":true,"additionalInfo":{"Authored_By":"Ana Martinez, Ana Martinez","Categories":"SCIENCE \/ Life Sciences \/ Biochemistry, MEDICAL \/ Biochemistry","Subjects":"Multiple sclerosis--Chemotherapy","Electronic_ISBN":"9781788018067","Print_ISBN":"9781788014588","Languages":"English","Published_Date":"2019-01-01","Resource_Type":"eBook.","Title_Abbreviations":"Emerging Drugs and Targets for Multiple Sclerosis","Volume":"00070"},"header":{"DbId":"nlebk","DbLabel":"eBook Collection (EBSCOhost)","An":"2204510","RelevancyScore":"1090","PubType":"eBook","PubTypeId":"ebook","PreciseRelevancyScore":"1090.09973144531"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=nlebk&AN=2204510&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=nlebk&AN=2204510&authtype=shib&custid=ns346513&group=main&profile=eds"}
["Ana Martinez, Ana Martinez","SCIENCE \/ Life Sciences \/ Biochemistry, MEDICAL \/ Biochemistry","Multiple sclerosis--Chemotherapy","9781788018067","9781788014588","English","2019-01-01","eBook.","Emerging Drugs and Targets for Multiple Sclerosis","00070"]
Description
Multiple sclerosis (MS) is a complex disease with a presumed autoimmune aetiology and few current effective treatments. Disease modifying therapies focus on the altering the natural course of relapsing and remitting MS, targeting the inflammatory response. Other targets involve tacking the cause of the disease – demyelination of axons through remyelination therapies. Due to several recent breakthroughs in the understanding of the pathophysiology of MS new targets for remyelination and immunomodulation are rapidly emerging. This book provides a comprehensive overview of drug discovery and development for the molecular basis of the disease, from new targets to drugs currently in clinical development, cellular and animal disease models to biomarkers for diagnosis and assessment in clinical trials. Emerging Drugs and Targets for Multiple Sclerosis is an ideal reference for any student or researcher interested in drug development for neurodegenerative diseases, autoimmune diseases and MS in particular.
